Transforming Management Strategies by
Integrating Biosimilars into the Treatment Landscape
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2023
Spring Managed Care Forum. If you participated in the live session,
you are not eligible for continuing education credits from this
This activity is valid from June 1, 2023 to August 1, 2024
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Biosimilar products are biologic products that are highly similar to
already approved biologic drugs developed for various indications.
While biosimilars have some differences compared with their
reference products, they are mandated to produce identical
similarity from their reference biologics in terms of clinical
safety and efficacy. As such, these biosimilar products promise to
foster unprecedented access to a wide range of life-saving biologics
while ensuring a rise in healthcare access and market
sustainability. Biosimilars are expected to have a significant
impact on healthcare as they revolutionize the treatments of many
disease states. Biosimilars have the potential to reduce healthcare
costs and expand patient access to biologic therapies. The high cost
of biologic drugs in immunology imposes a substantial burden on the
US healthcare system and has created numerous patient access
challenges. In recent years, there has been a shift in FDA approvals
for biosimilars, with multiple biosimilars for oncology-related
supportive care and disease-specific therapeutic indications
available on the US market. Healthcare professionals should be
appropriately educated about the cost-saving benefits associated
with biosimilars. These cost-savings may be significant for patient
populations affected by socioeconomic challenges or other healthcare
disparities that may limit access to treatment.
Upon completion of this
activity, participants will be able to:
Analyze clinical and nonclinical
barriers that affect the implementation of biosimilars in
Discuss the available and emerging
biosimilars for immunology, their indications, and their
Assess the efficacy, safety and
immunogenicity of biosimilars via clinical trial data and
real-world evidence in regard to treatment selection for
Identify strategies to discuss
biosimilar risks and benefits with patients who are currently
treated or considering treatment with a biologic
Examine the managed care
considerations for incorporating biosimilars into an effective
treatment plan and value-based care system to improve patient
||Gary Owens, MD
Gary Owens Associates
|(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Owens has served as a consultant for Sanofi and
Regeneron. His presentation has been reviewed for any
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue